Portfolio Update
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 December 2018
Net Assets | £209m |
Net Assets per share | 556p |
Share price | 570p |
Total value of unquoted investments | £30m |
Total number of portfolio companies | 61 |
Dividend | 4% of NAV per annum |
Top Ten Quoted Investments
Company Name | % NAV |
Incyte | 6.1 |
Vertex | 5.6 |
Celgene | 5.4 |
Genmab | 5.1 |
Gilead Sciences | 5.0 |
Regeneron | 4.4 |
Exelixis | 4.4 |
Illumina | 3.8 |
Neurocrine | 3.4 |
Biomarin | 3.0 |
| ----------- |
Total | 46.2 |
Geographical Allocation | % NAV |
US & Canada | 87 |
Europe | 13 |
| ----------- |
Total | 100 |
Quoted/Unquoted Allocation | % NAV |
Quoted | 85 |
Unquoted | 15 |
| ----------- |
Total | 100 |
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 44 |
Mid Cap =USD1-10BN | 33 |
Small Cap | 23 |
| ----------- |
Total | 100 |
NAV % by Therapeutic Areas | % NAV |
Oncology | 35 |
Rare diseases | 21 |
CNS | 10 |
Ophthalmology | 5 |
Infectious Diseases | 5 |
Tools | 4 |
Inflammation | 3 |
Medtech | 3 |
Metabolic | 0 |
Other | 14 |
| ----------- |
Total | 100 |
BNP Paribas Secretarial Services Limited
Company Secretary
17 JANUARY 2019
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.